Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates
Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER FOR SALE OF, OR THE SOLICITATION OF AN OFFER TO BUY, THE SECURITIES REFERRED TO HEREIN IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW.
Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million
- Capital increase by issuing 3,380,500 new shares at a purchase price of EUR 1.50 per new share
- Placement supported by existing and new shareholders
- Capital raise extends cash runway well into Q3 2026
- Proceeds provide financial runway and flexibility to realize strategic partnership for varoglutamstat in chronic kidney disease
Halle (Saale) / Munich, Germany, October 6, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (“Vivoryon“ or the”Company“), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it has completed a private placement of new shares to selected investors (“Offering”) with gross proceeds in the amount of EUR 5.1 million.
Pursuant to the results of the Offering, the Company will issue 3,380,500new ordinary shares at an offering price of EUR 1.50 per share, amounting to gross proceeds of EUR 5.1 million. The new shares issued pursuant to the Offering represent 12.9 % of Vivoryon’s existing issued share capital and will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights. As a consequence, the Company’s number of shares outstanding will increase to 29,614,337 and the Company’s share capital will increase from EUR 262,338.37 by EUR 33,805.00 to EUR 296,143.37 on completion of the Offering.
The private placement was supported by existing and new shareholders.
“This successful financing demonstrates the trust and confidence of both our longstanding and our new investors in our program and company strategy” said Frank Weber, MD, CEO of Vivoryon. “This is the first time Vivoryon has raised capital for the development of varoglutamstat in chronic kidney disease and it is an important step in moving the project forward including securing a strategic partnership. We are currently in discussions with several pharmaceutical companies, and this additional support provides us with the financial runway and financial flexibility to realize the right collaboration.”
The Company intends to use the proceeds from the private placement towards realizing the immediate next steps in ongoing clinical development of its lead candidate varoglutamstat, namely securing a partnership and, if required, additional funding to enable initiation of the planned Phase 2 study in diabetic kidney disease, as well as for general corporate purposes.
The Company now expects, based on its most recent financial and business plan, that its existing cash and cash equivalents including the proceeds from the private placement will be sufficient to fund its operating plans well into Q3 2026.
Koch Wertpapierhandels GmbH supported the private placement, Girolist AG acted as Transfer Agent.
The new shares are expected to be admitted to trading on Euronext Amsterdam on October 7, 2025 with delivery to the investors on or around October 9, 2025. The new shares will rank pari passu in all respects with the existing ordinary shares in the Company.
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com
Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.
For more information, please contact:
Investor Contact
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com
LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com
Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email: vivoryon@trophic.eu
Disclaimers
This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America (the “United States“), Australia, Canada, Japan or South Africa or any other jurisdiction in which such offer or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
This announcement is for information purposes only and is not intended to, and does not, constitute or form a part of any offer or solicitation to purchase or subscribe for new shares in the United States, Australia, Canada, Japan, South Africa or any other jurisdiction in which such offer or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
The new shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities law. No public offering of new shares is being made in the United States.
This announcement does not constitute a prospectus or an offer of new shares in the United States or in any other jurisdiction. No offer to sell or subscribe for new shares, or announcement of a forthcoming offer to sell or subscribe for new shares, or solicitation of any offer to buy or subscribe for new shares, or announcement of a forthcoming solicitation of any offer to buy or subscribe for, new shares will be made in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of such jurisdiction, and the distribution of this communication in jurisdictions may be similarly restricted. Persons into whose possession this communication comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the security laws of any such jurisdiction.
This announcement does not constitute a prospectus and has been prepared on the basis that any offers of new shares in any member state of the European Economic Area will be made pursuant to an exemption under Regulation (EU) 2017/1129 on prospectuses (the “Prospectus Regulation”). The information set forth in this announcement and any offer of new shares if made subsequently are in member states of the European Economic Area (i) only addressed to persons who are qualified investors (“Qualified Investors”) within the meaning of the Prospectus Regulation or (ii) in any other circumstances falling within article 1(4) of the Prospectus Regulation. This information must not be acted or relied on by, and any investment activity to which this information relates is not available to and may not be engaged with, persons in any member state of the European Economic Area who are not Qualified Investors. Any such investor will also be deemed to have represented and agreed that any new shares acquired by it in the contemplated private placement have not been acquired on behalf of persons other than such investor. This announcement is not an advertisement within the meaning of the Prospectus Regulation and does not constitute a prospectus and has not been approved by the Dutch Authority for the Financial Markets (Stichting Autoriteit Financiële Markten) or any European supervisory authority.
In the United Kingdom, this announcement and any other materials in relation to the new shares is only being distributed to, and is only directed at, and any investment or investment activity to which this announcement relates is available only to, and will be engaged in only with, persons who are “qualified investors” as defined in Regulation (EU) 2017/1129 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (the “UK Prospectus Regulation”) and in other instances where there is no obligation to publish a prospectus under the UK Prospectus Regulation or the Financial communicated (all such persons together being referred to as “Relevant Persons“). Persons who are not Relevant Persons should not take any action on the basis of this announcement and should not act or rely on it. Any investment activity to which this announcement and any other materials in relation to the new shares relates in the United Kingdom is available only to, and may be engaged in only with, Relevant Persons. No action has been taken by the Company that would permit an offer of new shares or the possession or distribution of these materials or any other offering or publicity material relating to such new shares in any jurisdiction where action for that purpose is required.
No prospectus has been filed with any securities commission or similar regulatory authority in Canada in connection with the private placement. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon this document or on the merits of the new shares and any representation to the contrary is an offence. The offer and sale of the new shares in Canada is being made on a private placement basis to investors resident in Alberta, British Columbia, Manitoba, Ontario and Quebec only and is exempt from the requirement that the Company prepare and file a prospectus under applicable Canadian securities laws. Any resale of the new shares acquired by a Canadian investor in this offering must be made in accordance with applicable Canadian securities laws, which resale restrictions may under certain circumstances apply to resales of the new shares outside of Canada. As applicable, each Canadian investor who purchases the new shares will be deemed to have represented to the Company and to each Joint Global Coordinator or its affiliate or agent from whom a purchase confirmation is received, as applicable, that the investor (i) is purchasing as principal, or is deemed to be purchasing as principal in accordance with applicable Canadian securities laws, for its own account and not as agent for the benefit of another person; (ii) is an “accredited investor” as such term is defined in section 1.1 of National Instrument 45-106 Prospectus Exemptions (“NI 45-106”) or, in Ontario, as such term is defined in section 73.3(1) of the Securities Act (Ontario); and (iii) is a “permitted client” as such term is defined in section 1.1 of National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations.
No prospectus or offering document has been or will be prepared in connection with the private placement. Any investment decision in connection with the private placement must be made solely on the basis of publicly available information relating to the Company and its shares. The contents of this announcement have been prepared by and is the sole responsibility of the Company. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or on its accuracy, fairness or completeness.
Market abuse regulation
This press release contains information within the meaning of Article 7(1) of the EU Market Abuse Regulation.